PMID- 36644538
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230612
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 11
IP  - 1
DP  - 2023 Jan
TI  - Endoscopic ultrasound-guided gastroenterostomy for the management of gastric 
      outlet obstruction: A large comparative study with long-term follow-up.
PG  - E60-E66
LID - 10.1055/a-1976-2279 [doi]
AB  - Background and study aims  Gastric outlet obstruction (GOO) is traditionally 
      managed with surgical gastroenterostomy (surgical-GE) and enteral stenting (ES). 
      Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is now a third option. 
      Large studies assessing their relative risks and benefits with adequate follow-up 
      are lacking. We conducted a comparative analysis of patients who underwent 
      EUS-GE, ES, or surgical-GE for GOO. Patients and methods  In this retrospective 
      comparative cohort study, consecutive patients presenting with GOO who underwent 
      EUS-GE, ES, or surgical-GE at two academic institutions were reviewed and 
      independently cross-edited to ensure accurate reporting. The primary outcome was 
      need for reintervention. Secondary outcomes were technical and clinical success, 
      length of hospital stay (LOS), and adverse events (AEs). Results  A total of 436 
      patients (232 EUS-GE, 131 ES, 73 surgical-GE) were included. The median duration 
      of follow-up of the entire cohort was 185.5 days (interquartile range 
      55.25-454.25 days). The rate of reintervention in the EUS-GE group was lower than 
      in the ES and surgical-GE groups (0.9 %, 12.2 %, and 13.7 %, P  < 0.0001). 
      Technical success was achieved in 98.3 %, 99.2 %, and 100 % ( P  = 0.58), and 
      clinical success was achieved in 98.3 %, 91.6 %, and 90.4 % ( P  < 0.0001) in the 
      EUS-GE, ES, and surgical-GE groups, respectively. The EUS-GE group had a shorter 
      LOS (2 days vs. 3 days vs. 5 days, P  < 0.0001) and a lower AE rate than the ES 
      and surgical-GE groups (8.6 % vs. 38.9 % vs. 27.4 %, P  < 0.0001). Conclusion  
      This large cohort study demonstrates the safety and palliation durability of 
      EUS-GE as an alternative strategy for GOO palliation in select patients.
CI  - The Author(s). This is an open access article published by Thieme under the terms 
      of the Creative Commons Attribution-NonDerivative-NonCommercial License, 
      permitting copying and reproduction so long as the original work is given 
      appropriate credit. Contents may not be used for commercial purposes, or adapted, 
      remixed, transformed or built upon. 
      (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Jaruvongvanich, Veeravich
AU  - Jaruvongvanich V
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Mahmoud, Tala
AU  - Mahmoud T
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Abu Dayyeh, Barham K
AU  - Abu Dayyeh BK
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Chandrasekhara, Vinay
AU  - Chandrasekhara V
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Law, Ryan
AU  - Law R
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Storm, Andrew C
AU  - Storm AC
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Levy, Michael J
AU  - Levy MJ
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Vargas, Eric J
AU  - Vargas EJ
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Marya, Neil B
AU  - Marya NB
AD  - Division of Gastroenterology, University of Massachusetts Medical School, 
      Worcester, Massachusetts, United States.
FAU - Abboud, Donna M
AU  - Abboud DM
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Ghazi, Rabih
AU  - Ghazi R
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Matar, Reem
AU  - Matar R
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Rapaka, Babusai
AU  - Rapaka B
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Buttar, Navtej
AU  - Buttar N
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, 
      United States.
FAU - Truty, Mark J
AU  - Truty MJ
AD  - Division of Surgery, Mayo Clinic, Rochester, Minnesota, United States.
FAU - Aerts, Maridi
AU  - Aerts M
AD  - Department of Gastroenterology-Hepatology, Universitair Ziekenhuis Brussel, Vrije 
      Universiteit Brussel, Brussels, Belgium.
FAU - Messaoudi, Nouredin
AU  - Messaoudi N
AD  - Department of Surgery, Universitair Ziekenhuis Brussel, Vrije Universiteit 
      Brussel, Brussels, Belgium.
FAU - Kunda, Rastislav
AU  - Kunda R
AD  - Department of Surgery, Department of Gastroenterology-Hepatology, Department of 
      Advanced Interventional Endoscopy, Universitair Ziekenhuis Brussel, Vrije 
      Universiteit Brussel, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20230113
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
CIN - Endosc Int Open. 2023 Jun 09;11(6):E566-E567. PMID: 37304248
PMC - PMC9839427
COIS- Competing interests Dr. Abu Dayyeh is a consultant for Endogenex, Endo-TAGSS, 
      Metamodix, and BFKW; is a consultant for and receives grant/research support from 
      USGI, Boston Scientific; receives grant/research support from Cairn Diagnostics, 
      Aspire Bariatrics; has speaker roles with Olympus, Johnson and Johnson; has 
      speaker and grant/research support from Medtronic, Endogastric solutions; and has 
      research support from Apollo Endosurgery, and Spatz Medical. Dr. Law is a 
      consultant for ConMed and Medtronic. Dr. Chandrasekhara is a consultant for 
      Boston Scientific, Covidien, and LP; a shareholder at Nevakar Corporation; and on 
      the medical advisory board for Interpace Diagnostics. Dr. Storm is a consultant 
      for Apollo Endosurgery, ERBE, GI Dynamics, and Olympus and received research 
      grant support from Apollo Endosurgery, Boston Scientific, Endo-TAGSS, Endogenex, 
      and Enterasense. Dr. Marya is a consultant for AnX Robotica. Dr. Kunda is a 
      consultant of Boston Scientific, Omega Medical Imaging, Apollo Endosurgery, and 
      Olympus, Ambu, M.I.Tech, Medconsgroup, EndiaTx, Q3 Medical - AMG International 
      and Tigen Pharma.
EDAT- 2023/01/17 06:00
MHDA- 2023/01/17 06:01
PMCR- 2023/01/01
CRDT- 2023/01/16 03:04
PHST- 2022/05/16 00:00 [received]
PHST- 2022/11/03 00:00 [accepted]
PHST- 2023/01/16 03:04 [entrez]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/01/17 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.1055/a-1976-2279 [doi]
PST - epublish
SO  - Endosc Int Open. 2023 Jan 13;11(1):E60-E66. doi: 10.1055/a-1976-2279. eCollection 
      2023 Jan.